What is the 13F Pro Quality Score for LXEO?

13F Pro ranks Lexeo Therapeutics, Inc. (LXEO) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View LXEO's current score at https://13fpro.ai/company/LXEO (free sign-up required for the full ranking).

Where does 13F Pro source LXEO data?

All Lexeo Therapeutics, Inc. fundamentals and ownership data come directly from SEC EDGAR. Lexeo Therapeutics, Inc. files with the SEC under CIK 1907108. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is LXEO in?

Lexeo Therapeutics, Inc. (LXEO) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is LXEO research updated on 13F Pro?

LXEO's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Lexeo Therapeutics, Inc.(LXEO)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqsmall

Institutional-grade research for retail investors

SEC EDGAR: CIK 1907108 LXEO stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Pending next ranking run

This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

LXEO Stock Analysis & AI Quality Score

Data updated 2026-07-26

AI stock analysis and institutional research for Lexeo Therapeutics, Inc. (LXEO), a Healthcare sector company. LXEO is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q2 2026), Lexeo Therapeutics, Inc. reports net income of $-25.9M, free cash flow of $-17.6M. Top institutional holders of LXEO by reported 13-F value include SUVRETTA CAPITAL MANAGEMENT, Affinity Asset Advisors, BlackRock, based on the most recent SEC filings. LXEO trades on the Nasdaq exchange and files with the SEC under CIK 1907108. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate LXEO daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Lexeo Therapeutics, Inc. directly from SEC EDGAR.

✦

Fun facts about Lexeo Therapeutics, Inc.

Quirks, history, and lore behind LXEO — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. clinical-stage biopharmaceutical company · listed on Nasdaq · focused on developing gene therapies for serious diseases.
2
The Numbers
A small-cap company with no product revenue yet — like most clinical-stage biotechs, it runs on cash from financings while its pipeline matures.
3
The History
Founded in the early 2020s and went public on Nasdaq, it was built around technology spun out of academic research in gene therapy delivery.
4
The Secret
Its pipeline zeroes in on diseases of the heart and nervous system, using AAV vectors to deliver corrective genes directly to diseased tissue.
5
The Lore
One of its lead programs targets Friedreich's ataxia — a rare, progressive neurological disease that has long been starved of treatment options.
6
The Giveaway
This New York-based gene therapy company trades under a ticker that starts with LX and is laser-focused on cardiogenetic and neurogenetic diseases no one else is rushing to treat.

▶ Think you know your stocks? Play the Daily Ticker

Net Income

Q2 2026

$-25.9M

Free Cash Flow

Q2 2026

$-17.6M

ROIC

Q2 2026

-47.7%

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

—FY 2025

FY22 $654.0KFY23 —FY24 —FY25 —

Net Income

-1.7% YoY

$-100.0MFY 2025

FY22 $-59.3MFY23 $-66.4MFY24 $-98.3MFY25 $-100.0M

Operating Income

-3.3% YoY

$-109.3MFY 2025

FY22 $-60.5MFY23 $-68.5MFY24 $-105.8MFY25 $-109.3M

EPS (Diluted)

+39.8% YoY

$-1.86FY 2025

FY22 $-36.36FY23 $-12.40FY24 $-3.09FY25 $-1.86

Total Assets

+82.9% YoY

$268.7MFY 2025

FY22 $97.1MFY23 $139.8MFY24 $146.9MFY25 $268.7M

Op. Cash Flow

-21.5% YoY

$-98.6MFY 2025

FY22 $-54.6MFY23 $-59.5MFY24 $-81.2MFY25 $-98.6M

Free Cash Flow

-21.2% YoY

$-99.0MFY 2025

FY22 $-55.2MFY23 $-59.6MFY24 $-81.6MFY25 $-99.0M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Revenue	—	—	—	$654.0K	—
Net Income	$-100.0M -1.7%	$-98.3M -48.1%	$-66.4M -12.0%	$-59.3M	—
Operating Income	$-109.3M -3.3%	$-105.8M -54.4%	$-68.5M -13.2%	$-60.5M	—
EPS (Diluted)	$-1.86 +39.8%	$-3.09 +75.1%	$-12.40 +65.9%	$-36.36	—
Total Assets	$268.7M +82.9%	$146.9M +5.1%	$139.8M +44.0%	$97.1M	—
Operating Cash Flow	$-98.6M -21.5%	$-81.2M -36.4%	$-59.5M -9.0%	$-54.6M	—
Free Cash Flow	$-99.0M -21.2%	$-81.6M -36.9%	$-59.6M -7.9%	$-55.2M	—

Get alerted when LXEO's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Lexeo Therapeutics, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of LXEO

SUVRETTA CAPITAL MANAGEMENT, LLC
$29.7M6,384,200 sh
Affinity Asset Advisors, LLC
$27.0M5,807,611 sh
BlackRock, Inc.
$26.7M5,739,455 sh
RA CAPITAL MANAGEMENT, L.P.
$23.3M5,000,000 sh
Frazier Life Sciences Management, L.P.
$22.5M4,824,725 sh
STATE STREET CORP
$20.3M4,354,757 sh
Vestal Point Capital, LP
$20.1M4,320,000 sh
Paradigm Biocapital Advisors LP
$19.4M4,175,382 sh
Jupiter Topco LLC
$18.4M3,954,691 sh
ORBIMED ADVISORS LLC
$18.4M3,947,850 sh

Fund	Value	Shares
SUVRETTA CAPITAL MANAGEMENT, LLC	$29.7M	6,384,200
Affinity Asset Advisors, LLC	$27.0M	5,807,611
BlackRock, Inc.	$26.7M	5,739,455
RA CAPITAL MANAGEMENT, L.P.	$23.3M	5,000,000
Frazier Life Sciences Management, L.P.	$22.5M	4,824,725
STATE STREET CORP	$20.3M	4,354,757
Vestal Point Capital, LP	$20.1M	4,320,000
Paradigm Biocapital Advisors LP	$19.4M	4,175,382
Jupiter Topco LLC	$18.4M	3,954,691
ORBIMED ADVISORS LLC	$18.4M	3,947,850

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put LXEO on your watchlist

Track score changes the day Lexeo Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is LXEO a good stock to buy?

13F Pro's AI-powered analysis of Lexeo Therapeutics, Inc. (LXEO) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for LXEO are available on the LXEO stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. LXEO is classified as a small company.

Which hedge funds own LXEO?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling LXEO. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Lexeo Therapeutics, Inc.'s investment landscape.